Pneumocystis jiroveci enfeksiyonu ve akciğer tutulumu

Elbuken, Gulsah

Pneumocystis jiroveci enfeksiyonu ve akciğer tutulumu

Gülşah ELBÜKEN (Gölköy Devlet Hastanesi, Ordu, Türkiye)

Uludağ Üniversitesi Tıp Fakültesi Dergisi

13 0

Yıl: 2007 Cilt: 33 Sayı: 2 Sayfa Aralığı: 97 - 103 Metin Dili: Türkçe İndeks Tarihi: 29-07-2022

Pneumocystis jiroveci enfeksiyonu ve akciğer tutulumu

Öz:

Pneumocystis jiroveci, bağışıklık sistemi baskılanmış hastalarda özellikle akciğer tutulumu ile seyreden fırsatçı bir patojendir. Pneumocystis jiroveci pnömonisinde klinik bulgular dispne, taşipne, nonprodüktif öksürük, ateş ve siyanozdur. Radyolojik olarak interstisyel pnömoni görünümü saptanır. Kültürde üretilemediğinden tanı klinik bulgular ile birlikte akciğer sekresyonunda organizmanın morfolojik olarak gösterilmesi veya fluoresan antikor ve moleküler yöntemler gibi daha duyarlı yöntemler ile saptanması ile konulabilmektedir. Diğer ilaç alternatifleri bulunmakla birlikte trimetoprim-sulfametaksazol profilaksi ve tedavide ilk seçenek olarak önerilmektedir.

Anahtar Kelime: Pneumocystis jirovecii Akciğer Pnömokist enfeksiyonu

Konular: Solunum Sistemi Mikrobiyoloji Hematoloji Onkoloji Enfeksiyon Hastalıkları Tıbbi Laboratuar Teknolojisi

Pneumocystis jiroveci infection and lung involvement

Öz:

Pneumocystis jiroveci is an oppurtunistic pathogen especially affecting lungs in immune-suppressed patients. The clinical findings in Pneumocystis jiroveci pneumonia are dyspnea, tachypnea, nonproductive cough, fever and cyanosis. Interstitial pneumonia is demonstrated radiologically. As it can not be cultured, the diagnosis is made with the presence of clinical findings and the morphological demonstration of the organism in the secreation of lung or detection with more sensitive methods like fluorescence antibody and molecular methods. Although other drug alternatives exist, trimethoprime-sulphamethaxasole is offered as the first option in the prophylaxis and treatment.

Anahtar Kelime: Pneumocystis Infections Pneumocystis jirovecii Lung

Konular: Solunum Sistemi Mikrobiyoloji Hematoloji Onkoloji Enfeksiyon Hastalıkları Tıbbi Laboratuar Teknolojisi

Belge Türü: Makale Makale Türü: Derleme Erişim Türü: Erişime Açık

1. Stringer JR, Beard CB, Miller RF, Wakefield AE. A new name (Pneumocystis jiroveci) for Pneumocystis from humans. Emerg. Infect. Dis. 2002; 6: 891-6.
2. Miller RF. Pneumocystis carinii infection in non AIDS patients. Current Opin. Infec.Dis.1999; 12:371.
3. Stringer JR, Walzer PD. Molecular biology and epidemiology of Pneumocystis carinii infection in AIDS. AIDS 1996;10: 561-571.
4. Frenkel JK. Pneumocystis. In: Binford CH, Connor DH, (eds). Pathology of tropical and extraordinary diseases. Washington, DC: Armed Forces Institute of Pathology; 1976;303-7.
5. Vavra J, Kucera K. Pneumocystis carinii Delanoe: its ultrastructure and ultrastructural affinities. J Protozool.1970;17: 463- 83.
6. Edman JC, Edman U, Cao M, Lundgren B, Kovacs JA, Santi DV. Isolation and expression of the Pneumocystis carinii dihydrofolate reductase gene. Proc. Natl. Acad. Sci. USA. 1989; 86: 8625- 8629.
7. Edman JC, Edman U, Cao M, Lundgren B, Kovacs JA, Santi DV. Isolation and expression of the Pneumocystis carinii thymidylate synthase gene. Proc. Natl. Acad. Sci. USA. 1989; 86: 6503- 6507.
8. Edman JC, Kovacs JA, Masur H, Santi DV, Elwood HJ, Sogin ML. Ribosomal RNA sequence shows Pneumocystis carinii to be a member of the fungi. Nature 1988; 11; 334: 519-22.
9. Eriksson, O. E. Pneumocystis carinii, a parasite in lungs of mammals, referred to a new family and order (Pneumocystidaceae, Pneumocystidales, Ascomycota). Systema Ascomycetum. 1994; 13:165-80.
10. Edman JC, Kovacs JA, Masur H, Santi DV, Elwood HJ, Sogin ML. Ribosomal RNA genes of Pneumocystis carinii. J Protozool. 1989; 36: 18-20.
11. Liu Y, Rocourt M, Pan S, Liu C, Leibowitz MJ. Sequence and variability of 5.8S and 26S rRNA genes of Pneumocystis carinii. Nucleic acids Res. 1992; 20: 3763- 72.
12. Lin H, Niu MT, Yoganathan T, Buck GA. Characterization of the rRNA- encoding genes and transcripts, and a group- I self splicing intron in Pneumocystis carinii. Gene. 1992; 119: 163- 73.
13. Lee CH, Helweg- Larsen J, Lundgren B, Lundgren JD, Tang X, Jin S, Li B, Bartlett MS, Lu JJ, Olsson M, Luvas SB, Roux P, Cargnel A, Atzori C, Matos O, SmithJW. Update on P.carinii f. sp. hominis typing based on nucleotide sequence variations in the internal transcribed spacer regions of rRNA genes. J Clin Microbiol. 1998; 36: 734-41.
14. Keeley SP, Stringer JR. Sequences of Pneumocystis carinii f. sp. hominis strais associated with recurrent pneumonia vary at multiple loci. J Clin Microbiol. 1997; 35: 2745- 47.
15. Latouche S, Ortona E, Mazars E, Margutti P, Tamburini E, Siracusano A, Guyot K, Nigou M, Roux P. Biodiversty of Pneumocystis carinii hominis: typing with different DNA regions. J Clin Microbiol. 1997; 35: 383-87.
16. Latouche S, Poirot JL, Bernard C, Roux P. Study of internal transcribed spacer and mitochondrial large- subunit genes of Pneumocystis carinii hominis isolated by repeated bronchoalveolar lavage from human immunodeficiency virus infected patients during one or several episodes of pneumonia. J Clin Microbiol. 1997; 35:1687-90.
17. Lu JJ, Bartlett MS, Shaw MM, Queener SF, Smith JW, Ortiz- Rivera M, Leibowitz MJ, Lee CH. Typing of Pneumocystis carinii strains that infect humans based on nucleotide sequence variations of internal transcribed spacers of rRNA genes. J Clin Microbiol. 1994; 32: 2904-12.
18. Tsolaki AG, Miller RF, Underwood AP, Banerji S, Wakefield AE. Genetic diversty at the internal transcribed spacer regions of the rRNA operon among isolates of Pneumocystis carinii from AIDS patients with recurrent pneumonia. J. Infect Dis. 1996; 174: 141-156.
19. Tang X, Bartlett MS, Smith JW, Lu JJ, Lee CH. Determination of copy number of rRNA genes in Pneumocystis carinii f. sp. hominis. J Clin Microbiol. 1998; 36: 2491- 94.
20. Hughes WT. Prologue to AIDS: the recognition of infectious opportunists. Medicine (Baltimore). 1998; 77: 227-32.
21. Hughes WT. Pneumocystis carinii pneumonia. N Engl J Med. 1977; 297: 1381- 83.
22. Weverling GJ, Mocroft A, Ledergerber B et al. Discontinuation of Pneumocystis carinii pneumonia prophylaxis after start of highly active antiretroviral therapy in HIV-1 infection. Lancet. 1999; 353: 1293- 98.
23. Vargas SL, Ponce CA, Gigliotti F, Ulloa AV, Prieto, Munoz MP, Hughes WT. Transmission of Pneumocystis carinii DNA from a patient with P. carinii pneumonia to immunocompetent contact healt care workers. J Clin Microbiol. 2000;38: 1536- 38.
24. Itatani CA, Marshall GJ. Ultrastructural morphology and staining characteristic of P.carinii in situ and from B.A.L. J Parasitol. 1998;74:700-12.
25. Ruffolo JJ. Pneumocystis carinii cell structure. In: Walzer PD, (ed). Pneumocystis carinii Pneumonia. New York: Marcel Dekker, 1994; 3-24.
26. Olsson M, Sukura A, Lindberg LA, et al. Detections of Pneumocystis carinii DNA by filtration of air. Scan J Infect Dis. 1996; 28: 279-82.
27. Bartlett MS, Vermund SH. Jacobs RL, et al. Detection of Pneumocystis carinii DNA in air samples: Likely environmental risk to susceptible persons. J Clin Microbiol. 1997; 35: 2511- 3.
28. Lundgren B, Elvin K, Rothman LP, et al. Transmission of Pneumocystis carinii from patients to hospital staff. Thorax. 1997;52:422- 4.
29. Rodriguez M, Fishman JA. Prevention of infection due to Pneumocystis spp. in human immunodeficiency virusnegative immunocompromised patients. Clin Microbiol Rev. 2004;17:770-82.
30. Nevez G, Guyot K, Totet A, Raccurt C, Dei- Cas E. Pulmonary colonisation with Pneumocystis carinii in an immunsupressed HIV negative patient: detection and typing of the fungus by PCR. J Med Microbiology. 2001; 50: 198- 200.
31. Ng V L, Yajko D M, Hadley W K. Extrapulmonary pneumocystosis. Clin Microbiol Rev. 1997; 10: 401–18.
32. Walzer PD. Pneumocystis carinii- New clinical spectrum? N England J Med. 1991; 324: 263- 265.
33. Hadley WK, Valerie LNG. Pneumocystis. In: Murray PR, Baron EJ, Pfaller MA, Tenover FC, Yolken RH (eds), Manuel of Clinical Microbiology, Washington: ASM Pres, 1999. 1200.
34. Hughes W.T. Pneumocystis carinii pneumonia. In: Gorbach SL, Barlett JG, Blacklow NR (eds), Infectious Diseases. Philadelphia: W.B. Saunders Co, 1998;601.
35. Walzer PD. Pneumocystis carinii. In: Mandell GL,Bennet JE, Dolin R, (eds) Principles and Practice of Infectious Diseases. New York: Churchill Livingstone; 1995. 2475.
36. DeLorenzo LJ, Huang CT, Maguire GP, Stone DJ. Roentgenographic patterns of Pneumocystis carinii pneumonia in 104 patients with AIDS. Chest. 1987;91:323-7.
37. Chaffey MH, Klein JS, Gamsu G, Blanc P, Golden JA. Radiographic distribution of Pneumocystis carinii pneumonia in patients with AIDS treated with prophylactic inhaled pentamidine. Radiology. 1990; 175:715-9.
38. Crans CA Jr, Boiselle PM. Imaging features of Pneumocystis carinii pneumonia. Crit Rev Diagn Imaging.1999;40:251-84.
39. Obaji J, Lee-Pack LR, Gutierrez C, Chan CK. The pulmonary effects of long-term exposure to aerosol pentamidine: a 5-year surveillance study in HIV-infected patients. Chest. 2003;123:1983-7.
40. Bergin CJ, Wirth RL, Berry GJ, Castellino RA. Pneumocystis carinii pneumonia: CT and HRCT observations. J Comput Assist Tomogr. 1990;14:756-9.
41. Üner A, Ok ÜZ, Korkmaz M. Pneumocystosis. In: Ozcel MA (ed). İmmün yetmezlikte önemi artan parazit hastalıkları. İzmir: Türk Parazitoloji Derneği yayın no: 12;1999.1-22.
42. Caliendo AM, Hewitt PL, Allegra JM, Keen A, Ruof KL, Ferraro MJ. Performance of a PCR Assay for detection of Pneumocystis carinii from respiratory specimens. J Clin Microbiol. 1998; 36: 979-82.
43. Quist J, Hill AR, Serum lactate dehidrogenase (LDH) in Pneumocystis carinii pneumonia, tuberculosis, and bacterial pneumonia. Chest. 1995; 108:415-8.
44. Skelly M, Hoffman J, Fabbri M, Holzman RS, Clarkson AB Jr, Merali S. S- adenosylmethionine concentrations in diagnosis of Pneumocystis carinii pneumonia. Lancet 2003; 361:1267-8.
45. Kim HK, Hughes WT, Feldman S. Studies of morphology and immunofluorescence of Pneumocystis carinii. Proc Soc Exp Biol Med. 1972;141:304-9.
46. Lung Parasites Incertae Sedis. Pneumocystis jiroveci (P.carinii). Carlo Denegri Foundation Web sayfası. (Resim III- III).
47. Kim HK, Hughes WT. Comparison of methods for identification of Pneumocystis carinii in pulmonary aspirates. Am J Clin Pathol. 1973;60:462-6.
48. Tiley SM, Marriott DJ, Harhness JL. An evaluation of four methods for the detection of Pneumocystis carinii in clinical specimens. Pathology. 1994;26: 325-8.
49. Lipschik G,Gill VJ, Lungren JD, Andravis VA, Nelson NA, Nielsen JO, Ognibene FP, Kovacs JA. Improved diagnosis of Pneumocystis carinii infection by polymerase chain reaction on induced sputum and blood. Lancet. 1992;340:203-6.
50. Olsson M, Elvin K, Löfdahl S, Linder E. Detection of Pneumocystis carinii DNA in sputum and bronchoalveolar lavage samples by polymerase chain reaction. J Clin Microbiol. 1993; 31:221–6.
51. Helweg-Larsen J, Jensen JS, Benfield T, Svendsen UG, Lundgren JD, Lundgren B, Diagnostic use of PCR for detection of Pneumocytis carinii in oral wash samples J Clin Microbiol. 1998;36: 2068-72.
52. Lu JJ, Chen CH, Barlett MS, Smith JW, Beckers PJ, Sieben M. Comparison of Six Different PCR Methods for Detection of Pneumocytis carinii. J Clin Microbiol. 1995;33:2785-8.
53. Başoğlu ÖK, İndüklenmiş balgamın tanısal değeri. Toraks Dergisi. 2001;2:53-61.
54. Yale SH, Limper AH. Pneumocystis carinii pneumoia in patients without acquired immunodeficiency syndrome: associated illness and prior corticosteroid therapy. Mayo Clin Proc. 1996;71: 5-13.
55. Sepkowitz KA. Opportunistic infections in patients with and patients without acquired immunodefiency syndrome. Clin Infect Dis. 2002;34:1098- 107.
56. Sepkowitz KA, Brown AE, Telzak EE, Gottlieb S, Armstrong D. Pneumocystis carinii pneumonia among patients without AIDS at a cancer hospital. JAMA. 1992;267:832-7.
57. Fischl MA, Dickinson GM, La Voie L. Safety and efficacy of sulfamethoxazole and trimethoprim chemoprophylaxis for Pneumocystis carinii pneumonia in AIDS. JAMA. 1988;259:1185-9.
58. U.S. Public Health Service Task Force on Antipnemocystis Prophylaxis for Patients with Human Immunodeficiency Virus. Recommendationsfor prophylaxis against Pneumocystis carinii pneumonia for adults and adolescents infected with human immmunodeficiency virus. MMWR 1992;41(RR-4):1- 11.
59. Ioannidis JP, Cappelleri JC, Skolnik PR, Lau J, Sacks HS. A meta-analysis of the relative efficacy and toxicity of Pneumocystis carinii prophylactic regimens. Arch Intern Med. 1996;156:177-88.
60. Moorman A, Von Bargen JC, Palella FJ, Holmberg SD. Pneumocystis carinii pneumonia incidence and chemoprophylaxis failure in ambulatory HIV-infected patients. HIV Outpatient Study (HOPS) Investigators. J Acquir Immune Defic Syndr Hum Retrovirol. 1998;19:182-8.
61. Masur H, Michelis MA, Greene JB, Onorato I, Stouwe RA, Holzman RS, Wormser G, Brettman L, Lange M, Murray HW, Cunningham-Rundles S. An outbreak of community-acquired Pneumocystis carinii pneumonia: initial manifestation of cellular immune dysfunction. N Engl J Med. 1981;305:1431-8.
62. Clumeck N. Primary prophylaxis against opportunistic infections in patients with AIDS. N Engl J Med. 1995;332:739-40.
63. Fishman JA. Prevention of Infection Due to Pneumocystis carinii. Antimicrob Agent Chemother. 1998;42: 995-1004.
64. Pearson RD, Hewlett EL. Use of pyrimethamine-sulfadoxine (Fansidar) in prophylaxis against chloroquine-resistant Plasmodium falciparum and Pneumocystis carinii. Ann Intern Med 1987;106:714-8.
65. Hughes WT. Pneumocystis carinii. In: Mandel GL, Douglas RG, (eds) Principles and practice of infectious diseases. New York: Wiley; 1978. 1549.
66. Sattler FR, Cowan R, Nielsen DM, Ruskin J. Trimethoprimsulfamethoxazole compared with pentamidine for treatment of Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. A prospective, noncrossover study. Ann Intern Med. 1988;109:280-7.
67. McLean I, Lucas CR, Mashford ML, Harman PJ. Modified trimethoprim-sulphamethoxazole doses in Pneumocystis carinii pneumonia. Lancet. 1987;2:857-8.
68. Kovacs JA, Hiemenz JW, Macher AM, Stover D, Murray HW, Shelhamer J, Lane HC, Urmacher C, Honig C, Longo DL. Pneumocystis carinii pneumonia: a comparison between patients with the acquired immunodeficiency syndrome and patients with other immunodeficiencies. Ann Intern Med. 1984;100:663-71.
69. Wharton JM, Coleman DL, Wofsy CB, Luce JM, Blumenfeld W, Hadley WK, Ingram-Drake L, Volberding PA, Hopewell PC. Trimethoprim-sulfamethoxazole or pentamidine for Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. A prospective randomized trial. Ann Intern Med. 1986;105:37-44.
70. Gordin FM, Simon GL, Wofsy CB, Mills J. Adverse reactions to trimethoprim-sulfamethoxazole in patients with the acquired immunodeficiency syndrome. Ann Intern Med. 1984;100:495-9.
71. Wofsy CB. Use of trimethoprim-sulfamethoxazole in the treatment of Pneumocystis carinii pneumonitis in patients with acquired immunodeficiency syndrome. Rev Infect Dis. 1987; 9:84- 94.
72. Salamone FR, Cunha BA. Update on pentamidine for the treatment of Pneumocystis carinii pneumonia. Clin Pharm. 1988;7:501-10.
73. Gonzalez A, Sager PT, Akil B, Rahimtoola SH, Bhandari AK. Pentamidine-induced torsade de pointes. Am Heart J. 1991;122:1489-92.
74. Quadrel MA, Atkin SH, Jaker MA. Delayed cardiotoxicity during treatment with intravenous pentamidine: two case reports and a review of the literature. Am Heart J. 1992; 123:1377-9.
75. Waskin H, Stehr-Green JK, Helmick CG, Sattler FR. Risk factors for hypoglycemia associated with pentamidine therapy for Pneumocystis pneumonia. JAMA. 1988; 260: 345-7.
76. Salmeron S, Petitpretz P, Katlama C, Herve P, Brivet F, Simonneau G, Duroux P, Regnier B. Pentamidine and pancreatitis. Ann Intern Med. 1986;105:140- 1.
77. Medina I, Mills J, Leoung G, Hopewell PC, Lee B, Modin G, Benowitz N, Wofsy CB. Oral therapy for Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. A controlled trial of trimethoprim-sulfamethoxazole versus trimethoprim-dapsone. N Engl J Med. 1990;323:776-82.
78. Sin DD, Shafran SD. Dapsone- and primaquine-induced methemoglobinemia in HIV-infected individuals. J Acquir Immune Defic Syndr Hum Retrovirol. 1996;12:477-81.
79. Spencer CM, Goa KL. Atovaquone. A review of its pharmacological properties and therapeutic efficacy in opportunistic infections. Drugs. 1995;50:176-96.
80. Hughes W, Kennedy W, Shenep J, et al. Safety and pharmacokinetics of 566C80, a hydroxynaphthoquinone with anti-P. carinii activity. In: Program and abstracts of the 30th Interscience Conference on Antimicrobial Agents and Chemotherapy; October 21-24, 1990; Atlanta. Abstract 861.
81. Hughes WT, Kennedy W, Shenep JL, Flynn PM, Hetherington SV, Fullen G, Lancaster DJ, Stein DS, Palte S, Rosenbaum D. Safety and pharmacokinetics of 566C80, a hydroxynaphthoquinone with anti-Pneumocystis carinii activity: a phase I study in human immunodeficiency virus (HIV)- infected men. J Infect Dis. 1991;163:843-8.
82. Falloon J, Kovacs J, Hughes W, O'Neill D, Polis M, Davey RT, Jr., Rogers M, LaFon S, Feuerstein I, Lancaster D, et al. A preliminary evaluation of 566C80 for the treatment of Pneumocystis pneumonia in patients with the acquired immunodeficiency syndrome. N Engl J Med. 1991;325:1534-8.
83. Toma E, Fournier S, Poisson H, et al. Clindamycin/ primaquine for P. carinii pneumonia in AIDS. In: Program and abstracts of the V International Conference on AIDS; June 4-9, 1989; Montreal. Abstract T.B.O.31.
84. Fulton B, Wagstaff AJ, McTavish D. Trimetrexate. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in the treatment of Pneumocystis carinii pneumonia. Drugs. 1995;49:563-76.
85. Sattler FR, Allegra CJ, Verdegem TD, Akil B, Tuazon CU, Hughlett C, Ogata-Arakaki D, Feinberg J, Shelhamer J, Lane HC, et al. Trimetrexate-leucovorin dosage evaluation study for treatment of Pneumocystis carinii pneumonia. J Infect Dis. 1990;161:91-6.
86. Gilman TM; Boylen CT; Sattler FR. Pyrimethaminesulfadiazine for treating Pneumocystis carinii pneumonia and toxoplasmosis in AIDS. Clin Pharm. 1989;8:84-7.
87. Stein CR, Poole C, Kazanjian P, Meshnick SR. Sulfa use, dihydropteroate synthase mutations, and Pneumocystis jirovecii pneumonia. Emerg Infect Dis. 2004;10:1760-5.
88. Pareja JG, Garland R, Kolziel H. Use of adjunctive corticosteroids in severe adult non-HIV Pneumocystis carinii pneumonia. Chest. 1998;113:1215-24.
89. Patel N, Koziel H. Pneumocystis jiroveci pneumonia in adult patients with AIDS: treatment strategies and emerging challenges to antimicrobial therapy. Treat Respir Med. 2004;3:381-97.

APA	Elbuken G (2007). Pneumocystis jiroveci enfeksiyonu ve akciğer tutulumu. , 97 - 103.
Chicago	Elbuken Gulsah Pneumocystis jiroveci enfeksiyonu ve akciğer tutulumu. (2007): 97 - 103.
MLA	Elbuken Gulsah Pneumocystis jiroveci enfeksiyonu ve akciğer tutulumu. , 2007, ss.97 - 103.
AMA	Elbuken G Pneumocystis jiroveci enfeksiyonu ve akciğer tutulumu. . 2007; 97 - 103.
Vancouver	Elbuken G Pneumocystis jiroveci enfeksiyonu ve akciğer tutulumu. . 2007; 97 - 103.
IEEE	Elbuken G "Pneumocystis jiroveci enfeksiyonu ve akciğer tutulumu." , ss.97 - 103, 2007.
ISNAD	Elbuken, Gulsah. "Pneumocystis jiroveci enfeksiyonu ve akciğer tutulumu". (2007), 97-103.

APA	Elbuken G (2007). Pneumocystis jiroveci enfeksiyonu ve akciğer tutulumu. Uludağ Üniversitesi Tıp Fakültesi Dergisi, 33(2), 97 - 103.
Chicago	Elbuken Gulsah Pneumocystis jiroveci enfeksiyonu ve akciğer tutulumu. Uludağ Üniversitesi Tıp Fakültesi Dergisi 33, no.2 (2007): 97 - 103.
MLA	Elbuken Gulsah Pneumocystis jiroveci enfeksiyonu ve akciğer tutulumu. Uludağ Üniversitesi Tıp Fakültesi Dergisi, vol.33, no.2, 2007, ss.97 - 103.
AMA	Elbuken G Pneumocystis jiroveci enfeksiyonu ve akciğer tutulumu. Uludağ Üniversitesi Tıp Fakültesi Dergisi. 2007; 33(2): 97 - 103.
Vancouver	Elbuken G Pneumocystis jiroveci enfeksiyonu ve akciğer tutulumu. Uludağ Üniversitesi Tıp Fakültesi Dergisi. 2007; 33(2): 97 - 103.
IEEE	Elbuken G "Pneumocystis jiroveci enfeksiyonu ve akciğer tutulumu." Uludağ Üniversitesi Tıp Fakültesi Dergisi, 33, ss.97 - 103, 2007.
ISNAD	Elbuken, Gulsah. "Pneumocystis jiroveci enfeksiyonu ve akciğer tutulumu". Uludağ Üniversitesi Tıp Fakültesi Dergisi 33/2 (2007), 97-103.